Atyr Pharma Inc


LIFE

Price

1.95


Change

-0.05


High

1.95


Low

1.95


Avg Volume

702,057


PE Ratio

-2.07


52 Week High

2.7


52 Week Low

1.08



Profile

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signalling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease , a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.